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Evidence from high-income settings has shown 
that HIV patients experience a high physical and 
psychological symptom burden in the presence 
of antiretroviral therapy (ART).[1,2] This symptom 
burden has been associated with sexual risk-taking,[3] 
poor adherence,[4] treatment switching[5] and viral rebound.[6] 
HIV patients perceive that their symptoms remain untreated.[7,8] 
This perception is supported by evidence that physicians detect three-
fold fewer HIV-related symptoms than their patients report.[9] Doctors 
tend to overlook the assessment of pain and other treatable symptoms, 
instead focusing on symptoms that are physically measurable such as 
fever and weight loss, and are more likely to ask about symptoms in 
HIV patients perceived to be severely ill.[10] 
The World Health Organization (WHO) advocates pain and symptom 
control as an essential component of HIV clinical care.[11] A significant 
proportion of patients receiving ART experience drug toxicities such 
as peripheral neuropathy and gastrointestinal problems,[12] requiring 
drug discontinuation or treatment change within, and between, classes 
of ART.[13] Investigation into prevalence and correlates of HIV-related 
symptoms is required to inform clinical practice and thereby improve 
clinical outcomes and quality of life in the presence of ART.[14,15]
The vast majority of data on pain and symptom prevalence have 
been reported from the pre-ART era in patients in high-income 
countries with AIDS-defining illnesses. As there are fewer treatment 
options available in low- and middle-income countries, adherence 
must be optimised and movement between classes of drugs minimised. 
Given the relationship between symptom burden, poor adherence, 
treatment switching and viral rebound, symptom data are urgently 
needed to inform patient assessment and management in Africa.
The prevalence and high burden/high frequency of symptoms 
for patients receiving ART and those not receiving ART have been 
reported previously.[16] We report the seven-day period prevalence, 
burden and correlates of pain, and other physical and psychological 
symptoms, among HIV patients receiving ART in three public sector 
HIV clinics in South Africa (SA).
Methods
Study design 
The study design was cross-sectional self-report with additional 
clinical data extracted from patient records. 
The study was approved by the Committee for Research in Human 
Subjects (Medical) at the University of the Witwatersrand and by the 
Human Research Ethics Committee of the University of Cape Town. 
Setting
The research was conducted in the outpatient adult HIV treatment 
clinics within three academic hospitals in Johannesburg, SA, which 
adhere to the most recent SA national ART guidelines. At the time 
of data collection, the clinics had implemented the recent change 
in the national guidelines to initiate ART in patients with a CD4+ 
count <200  cells/μl, regardless of stage; those with a CD4+ count 
<350  cells/ μl and pregnant or co-infected with tuberculosis (TB); 
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those who are WHO stage 4 regardless of CD4+ count and all patients 
with drug-resistant TB.[17] 
Recruitment 
Inclusion criteria accounted for HIV outpatients aged 18 years or 
older receiving ART and able to give informed consent to participate 
in data collection in one of the three most common languages: 
English, isiZulu and Sesotho. Simple random sampling was used 
by inviting every fifth patient attending the clinic to participate, on 
days selected at random over an eight-month period in 2009 - 2010. 
Informed consent was obtained from participants. 
Data collection
Data were collected using self-report (demographics, symptom 
prevalence and burden) and extraction of data from files (CD4+ 
count at treatment initiation, time since treatment initiation, most 
recent CD4+ count, most recent viral load, whether the patient had 
switched treatment, WHO disease stage). The seven-day period 
prevalence and associated burden of symptoms was measured using 
the Memorial Symptom Assessment Scale Short Form (MSAS-
SF). [18] The MSAS-SF measures 28 physical and four psychological 
symptoms and provides three subscale indices of Physical Symptom 
Distress (MSAS-Phys), Psychological Symptom Distress (MSAS-
Psych) and Global Distress Index (MSAS-GDI).[14] Each of these 
three subscales has a possible score range of 0 - 4. The MSAS-SF has 
been widely used in HIV populations.[1,2,19,20] Finally, the research 
nurse scored the patient on the Karnofsky Performance Scale, which 
is a measure of physical performance scored from 0 (dead) to 100 
(normal) in bands of 10[21] and is a commonly used measure of 
performance in HIV populations.[22]
Owing to potential literacy limitations in the population sampled, 
a research nurse read aloud each self-reported question and recorded 
the response to reduce any potential bias through mixed self-
completion and researcher-administered questionnaires. Information 
and consent forms and the questionnaire were translated from 
English into isiZulu and Sesotho by forward and back translation 
and the interview was conducted in the patient’s language of choice. 
Analysis 
Descriptive data were generated for the sample characteristics. The 
most common symptoms have been previously reported.[16] The 
MSAS-SF subscales and total number of symptoms were calculated. 
Subsequently, the following analyses were conducted. Univariate 
linear regression analyses were conducted to test the association of 
independent covariates with the following four dependent variables: 
(i) MSAS-Phys; (ii) MSAS-Psych; (iii) MSAS-GDI; and (iv) total 
symptom burden. Each of these four dependent variables formed a 
separate model in the subsequent multivariate analyses described 
below. As the burden scores were not normally distributed (data 
plotting showing a left-skew), they were transformed into tertiles. 
Independent variables entered in univariate analysis were: age 
(continuous); gender (two levels of male/female); WHO stage (three 
levels of stage 1, 2, 3 or 4); CD4+ count at ART initiation transformed 
into quartiles; whether the patient had switched ART regimen 
(two levels: yes/no); current viral load (two levels: detectable/not 
detectable); current CD4+ count (continuous); and time receiving 
ART (years). 
Following each univariate regression, multivariate regressions 
models were constructed. Independent variables from the univariate 
analyses above were entered into the multivariate model if significant 
at the 25% level.[23] For each independent variable, the unstandardised 
β coefficient and the 95% confidence interval (CI) were calculated. For 
each multivariate model, the F-value for the model and the r2 were 
calculated. Cases with missing data were excluded from the multivariate 
models. All analyses were conducted using SPSS (version 19). 
Results
Sample characteristics 
A total of 378 patients participated (Table  1). The mean age of the 
patients was 40.3 years, the majority were female (76.2%) and of 
black ethnicity (98.1%). Participants had been receiving treatment 
for an average of three years and had a current average CD4+ count 
of 355.85  cells/μl (standard deviation (SD) ±219.26). According to 
the latest results available in the participants’ records, around one-
quarter of the sample (n=99; 28.6%) did not have viral suppression, 
and almost half (n=172; 45.5%) had switched ART regimen. 
Symptomatology
The mean number of symptoms (of a possible total of 32) was 10.05 
(SD ±5.66; range 1 - 28). The symptom prevalence and burden are 
presented in descending order of prevalence in Table  2. Three of 
the four psychological symptoms (sad, irritable and worrying) were 
among the ten most prevalent symptoms. The ten symptoms with the 
highest burden (i.e. scored using the worst two response categories) 
were: numbness and tingling in the hands/feet (37% of whole 
sample); feeling irritable (36.8%); problems with sexual interest or 
function (35.1%); worry (34.4%); not looking like myself (34.4%); 
feeling sad (30.7%); pain (29.1%); weight loss (24.8%); sweats 
(22.7%); and feeling nervous (20.6%). 
Table 1. Sample characteristics (N=378)
Age (years), mean (±SD) 40.34 (±9.16)
Female gender, n (%) 288 (76.2)
Ethnicity, n (%)
Black 371 (98.1)
Mixed ancestry 5 (1.3)
White 2 (0.5)
WHO stage, n (%)
Stage 1 98 (25.9)
Stage 2 246 (65.1)
Stage 3 29 (7.7)
Stage 4 5 (1.3)
KPS, median (IQR) 90 (90 - 90)*
CD4+ count (cells/ml)
Pre-ART, median (IQR) 93 (40.5 - 158.25)
Current, mean (±SD) 355.85 (±219.26)
Years receiving ART, mean (±SD) 3.04 (±1.83)
Patients with undetectable VL, n (%) 279 (71.4)†
Current VL for those detectable (copies/ml), 
median (IQR)
2500 (142 - 67 000)
Switched ART regimen (no), n (%) 206 (54.5)
WHO = World Health Organization; KPS = Karnofsky Performance Scale;  
IQR = interquartile range; ART = antiretroviral therapy; VL = viral load.
*Data missing for 4 patients.†Data missing for 33 patients.
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Regression analyses: Associations with symptom 
burden indices 
The univariate analysis is presented in Table  3. In multivariate 
analysis (Table  4), for the first model (MSAS-Phys; F=4.878; 
p<0.001; r2=8%) the following independent associations were 
identified. Higher physical symptom distress was associated with 
greater age (β=0.009; 95% CI 0.001 - 0.018; p=0.036); female gender 
(β=-0.207; 95% CI -0.399 - -0.016; p=0.034); and greater number 
of years receiving ART (β=0.083; 95% CI 0.037 - 0.129; p≤0.001). 
For the second model (MSAS-Psych; F=6.967; p<0.001; r2=9%), 
higher psychological distress was associated with later WHO stage 
(β=0.359; 95% CI 0.202 - 0.516; p≤0.001) and greater number of 
years receiving treatment (β=0.068; 95% CI 0.019 - 0.117; p=0.007). 
For the third model (MSAS-GDI; F=5.152; p<0.001; r2=10%), 
higher global symptom distress was associated with later WHO 
stage (β=0.365; 95% CI 0.204 - 0.526; p<0.001) and greater number 
of years receiving ART (β=0.065; 95% CI 0.016 - 0.115; p=0.010). 
For the fourth model (total symptom distress, model F=6.407; 
p<0.001; r2=10%), higher total symptom distress was associated 
with later WHO stage (β=0.308; 96% CI 0.150 - 0.465; p<0.001) and 
greater number of years receiving ART (β=0.081; 95% CI 0.032 - 
0.130; p=0.001). 
Table 2. Seven-day period prevalence and burden of symptoms (N=378)
Physical symptoms Prevalence
Distress, n (%*)
N/A None A little bit Somewhat Quite a bit Very much
 Numbness/tingling in hands 
and feet
226 (59.8) 152 (40.2) 16 (4.5) 28 (7.4) 42 (11.1) 36 (9.5) 104 (27.5)
 Problems with sexual interest 
or activity
196 (51.9) 182 (48.1) 14 (3.7) 18 (4.5) 31 (8.2) 27 (7.1) 106 (28)
Pain 190 (50.3) 188 (49.7) 15 (4.0) 29 (7.7) 36 (9.5) 27 (7.1) 83 (22)
‘I don’t look like myself ’ 182 (48.1) 196 (51.9) 6 (1.6) 17 (4.8) 29 (7.7) 20 (5.3) 110 (29.1)
Lack of energy 151 (39.9) 227 (60.1) 8 (2.1) 25 (6.6) 45 (11.9) 20 (5.3) 53 (14.0)
Sweats 148 (39.2) 230 (60.8) 7 (1.9) 22 (5.8) 32 (8.5) 27 (7.1) 60 (15.6)
Weight loss 144 (38.1) 234 (61.9) 6 (1.6) 24 (6.3) 24 (6.3) 17 (4.5) 73 (19.3)
Feeling bloated 143 (37.8) 235 (62.2) 10 (2.6) 38 (10.1) 24 (6.3) 35 (9.3) 36 (9.5)
Feeling drowsy 135 (35.7) 243 (64.3) 15 (4.0) 41 (10.8) 20 (5.6) 23 (6.1) 6 (9.5)
Changes in skin 132 (34.9) 246 (65.1) 13 (3.4) 27 (7.1) 26 (6.9) 14 (3.7) 52 (13.8)
Difficulty concentrating 128 (33.9) 250 (66.1) 9 (2.4) 30 (7.9) 28 (7.4) 22 (5.8) 40 (10.6)
Constipation 118 (31.2) 260 (68.8) 9 (2.4) 29 (7.7) 27 (7.1) 222 (6.1) 31 (8.2)
Itching 111 (29.4) 267 (70.6) 8 (2.1) 24 (6.6) 24 (6.3) 21 (5.6) 34 (9.0)
Lack of appetite 95 (25.1) 283 (74.9) 6 (1.6) 12 (3.2) 21 (5.6) 19 (5.0) 37 (9.8)
Cough 94 (24.9) 284 (75.1) 21 (5.6) 29 (7.7) 15 (4) 8 (2.1) 21 (5.6)
Dizziness 91 (24.1) 287 (75.9) 8 (2.1) 24 (6.3) 16 (4.2) 12 (3.2) 31 (8.2)
Swelling of arms or legs 88 (23.3) 290 (76.7) 4 (1.1) 21 (5.6) 21 (5.6) 11 (2.9) 31 (8.2)
Difficulty sleeping 86 (22.8) 292 (77.2) 8 (1.9) 13 (3.4) 12 (3.2) 14 (3.4) 39 (10.3)
Dry mouth 83 (22.0) 295 (78.0) 9 (2.4) 19 (5.0) 14 (3.0) 17 (4.8) 24 (6.3)
Shortness of breath 68 (17.7) 310 (82.3) 3 (0.8) 12 (3.2) 13 (3.4) 13 (3.2) 27 (7.1)
Nausea 64 (16.9) 314 (83.1) 6 (1.6) 22 (5.8) 11 (2.9) 7 (1.9) 18 (4.8)
Diarrhoea 58 (15.3) 320 (84.7) 8 (1.9) 16 (4.2) 10 (2.6) 10 (2.6) 14 (3.7)
Problems with urination 54 (14.3) 324 (85.7) 0 (0) 12 (3.2) 11 (2.9) 8 (2.1) 23 (6.1)
Mouth sores 52 (13.8) 327 (86.2) 20 (5.0) 19 (5.0) 14 (3.7) 4 (1.1) 14 (3.7)
Change in the way food tastes 49 (13.0) 329 (87.0) 5 (1.3) 8 (2.1) 5 (1.3) 11 (2.9) 20 (5.3)
Hair loss 35 (9.3) 343 (90.7) 4 (1.1) 8 (2.1) 5 (1.3) 3 (0.8) 15 (4.0)
Vomiting 23 (6.1) 355 (93.9) 4 (1.1) 11 (2.9) 1 (0.3) 3 (0.8) 4 (1.1)
Difficulty swallowing 15 (4.0) 363 (96.0) 1 (0.3) 5 (1.3) 1 (0.3) 4 (1.1) 4 (1.1)
Psychological symptoms Prevalence N/A Rarely Occasionally Frequently Almost constantly
Feeling sad 242 (64.0) 136 (36.0) 61 (16.1) 65 (17.2) 31 (8.2) 85 (22.5)
Feeling irritable 233 (61.6) 145 (38.4) 39 (10.3) 55 (14.3) 40 (10.6) 99 (26.2)
Worrying 231 (60.8) 147 (39.2) 55 (14.8) 46 (12.2) 37 (9.8) 93 (24.6)
Feeling nervous 149 (39.5) 229 (60.5) 38 (10.6) 32 (8.5) 22 (5.8) 56 (14.8)
N/A = not present.
*Do not all add to 100% due to rounding.
RESEARCH
122       February 2014, Vol. 104, No. 2
Table 3. Associations of covariates with symptom indices: Univariate analysis 
Dependent 
variable
Independent variables
Age Gender WHO stage 
CD4+ count 
pre-ART 
Years 
receiving 
ART
Current 
CD4+ count
Detectable 
VL
ART regimen
switched
Model 1: MSAS-Phys (N=335)
β 0.009 -0.238 0.157 0.047 0.087 0.000 -0.110 0.115 
95% CI 0.001 - 0.018 -0.425 - 0.051 0.017 - 0.298 -0.026 - 0.119 0.044 - 0.131 -0.001 - 0.000 -0.315 - 0.095 -0.046 - 0.276
p-value 0.036* 0.013* 0.029* 0.206* 0.014* 0.463 0.291 0.160*
Model 2: MSAS-Psych (N=335)
β 0.003 -0.195 -0.373 0.023 -0.116 <0.001 -0.206 0.102
95% CI -0.006 - 0.012 -0.39 - 0.00 0.231 - 0.515 -0.052 - 0.097 -0.078 - 0.31 0.000 - 0.001 -0.416 - 0.005 -0.065 - 0.269
p-value 0.567 0.050* ≤0.001* 0.553 0.240* 0.420 0.055* 0.229*
Model 3: MSAS-GDI (N=335)
β <0.001 -0.194 0.365 0.046 0.065 - -0.112 0.102
95% CI -0.010 - 0.009 -0.402 - -0.014 0.204 - 0.526 -0.032 - 0.123 0.016 - 0.115 - -0.328 - 0.104 -0.168 - 0.192
p-value 0.951 0.067 <0.001* 0.245 ≤0.010* - 0.308 0.895
Model 4: Total symptom burden (N=335)
β 0.012 -0.173 0.362 - 0.101 - -0.154 0.198
95% CI 0.003 - 0.021 -0.368 - 0.022 0.220 - 0.504 - 0.056 - 0.146 - -0.366 - 0.058 0.032 - 0.364
p-value 0.010* 0.081* ≤0.001* - ≤0.001* - 0.153* 0.019*
WHO = World Health Organization; ART = antiretroviral therapy; VL = viral load; MSAS = Memorial Symptom Assessment Scale; MSAS-Phys = MSAS Physical Symptom Distress Index; 
MSAS-Psych = MSAS Psychological Symptom Distress Index; MSAS-GDI = MSAS Global Distress Index; CI = confidence interval.
*Entered into multivariate model.
Table 4. Associations of covariates with symptom indices: Multivariate analysis
Dependent 
variable
Independent variables
Age Gender WHO stage 
CD4+ count 
pre-ART 
Years 
receiving 
ART
Current 
CD4+ count
Detectable 
VL
ART 
regimen
switched
Model 1: MSAS-Phys (N=376)
β 0.009 -0.207 0.111 0.041 0.083 - - -0.041
95% CI 0.001 - 0.018 -0.399 - -0.016 -0.033 - 0.255 -0.031 - 0.113 0.037 - 0.129 - - -0.210 - 0.129
p-value 0.036* 0.034* 0.131 0.263 ≤0.001‡ - - 0.637
Model 2: MSAS-Psych (N=377)
β - -0.160 0.359 - 0.068 - -0.121 0.051
95% CI - -0.362 - 0.042 0.202 - 0.516 - 0.019 - 0.117 - -0.327 - 0.086 -0.227 - 0.125
p-value - 0.121 ≤0.001‡ - 0.007† - 0.252 0.567
Model 3: MSAS-GDI (N=376)
β <0.001 -0.194 0.365 0.046 0.065 - -0.112 0.102
95% CI -0.010 - 0.009 -0.402 -  -0.014 0.204 - 0.526 -0.032 - 0.123 0.016 - 0.115 - -0.328 - -0.104 -0.168 - 0.192
p-value 0.951 0.067 <0.001‡ 0.245 ≤0.010† - 0.308 0.895
Model 4: Total symptom burden (N=375)
β 0.008 -0.174 0.308 - 0.081 - -0.032 0.037
95% CI -0.001 - 0.018 -0.378 - 0.030 0.150 - 0.465 - 0.032 - 0.130 - -0.244 - 0.180 0.140 - 0.214
p-value 0.087 0.095 ≤0.001‡ - 0.001‡ - 0.767 0.679
WHO = World Health Organization; ART = antiretroviral therapy; VL = viral load; MSAS = Memorial Symptom Assessment Scale; MSAS-Phys = MSAS Physical Symptom Distress Index; 
MSAS-Psych = MSAS Psychological Symptom Distress Index; MSAS-GDI = MSAS Global Distress Index; CI = confidence interval.
*Significant at p<0.05.
†Significant at p<0.01.
‡Significant at p<0.001.
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Discussion
These data reveal a high prevalence and burden of symptoms among 
HIV patients receiving ART in SA, which persists despite relatively good 
physical function and the majority having been receiving treatment for 
several years. Seven symptoms were scored in the worst two categories 
of burden by around one-third of the sample, and these symptoms were 
psychological and physical, including a symptom indicative of peripheral 
neuropathy as well as other pain and sexual dysfunction. 
There were a number of associations with symptom burden. 
Although greater age and female gender were associated with physical 
symptom distress, a consistent relationship was identified between 
worse symptom indices and greater number of years receiving ART. 
This may be related to the greater number of years of having HIV 
infection, and to the toxicity of treatment. In addition to clinician 
monitoring of patient wellbeing when beginning treatment, these 
data suggest that those who are treatment-experienced should have 
their symptom burden assessed alongside measurement of virological 
efficacy. Although there was a high symptom burden for the whole 
sample, the data also suggest that those with more advanced disease 
(as measured by WHO staging) may experience a greater burden. 
A systematic review has demonstrated that palliative care can 
effectively control these burdensome problems in HIV populations. [24] 
It is essential that clinical medicine takes account of patient self-
reported problems to improve quality of care.[25] Our data on pain and 
symptom prevalence, and associated distress, support the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) and WHO policy that 
palliative care is necessary throughout the HIV disease trajectory 
alongside ART. [11,26] In light of the data suggesting that uncontrolled 
symptoms adversely affect quality of life[8,27] and are associated with 
poor adherence,[4] sexual risk-taking,[3] treatment switching[5] and 
viral rebound,[6] we recommend that clinicians regularly assess their 
patients’ physical and psychological self-reported symptoms. 
Study limitations
There were a number of methodological limitations to our study. 
Firstly, the cross-sectional nature of the design meant that we could 
not draw causal relationships to symptom burden. Second, the 
reliance on file data, rather than collecting new primary data on 
clinical outcomes, may have introduced some inaccuracy. 
Conclusion
Within Africa, symptom prevalence data have been reported in 
newly diagnosed HIV patients preparing for treatment,[19] and among 
patients with advanced disease.[1,20] Our study has built on the small 
body of prior evidence on prevalence and correlates of symptom 
burden in African patients[28-30] and supports prior findings that 
symptoms persist despite ART. Our data indicate that, alongside 
treatment to prolong life, clinical care should include detailed 
assessment and control of pain and symptoms to maximise quality 
of life and treatment benefit. In particular, our data suggest that 
although all patients should have their symptoms assessed regularly 
and controlled, those who have spent a longer time receiving ART, 
and those with more advanced disease, may require greater attention. 
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